

WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding FXR, wherein said antisense compound
5 specifically hybridizes with and inhibits the expression of FXR.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein said antisense oligonucleotide comprises at least 8 contiguous nucleic acids of a nucleic
10 acid sequence of SEQ ID NO.1 – SEQ ID NO:2138.
4. The antisense compound of claim 2 wherein said antisense oligonucleotide comprises a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:2138.
5. The antisense compound of claim 2 wherein said antisense
15 oligonucleotide consists of at least 8 contiguous nucleic acids of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:2138.
6. The antisense compound of claim 2 wherein said antisense oligonucleotide consists of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:2138.
- 20 7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
8. The antisense compound of claim 7 wherein the modified internucleoside linkage is a phosphorothioate linkage.
9. The antisense compound of claim 2 or 7 wherein the antisense
25 oligonucleotide comprises at least one modified sugar moiety.
10. The antisense compound of claim 9 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

11. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
12. The antisense compound of claim 11 wherein the modified nucleobase is a 5-methylcytosine.
- 5 13. The antisense compound of claim 9 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
14. The antisense compound of claim 13 wherein the modified nucleobase is a 5-methylcytosine.
15. The antisense compound of claim 2 wherein the antisense
10 oligonucleotide is a chimeric oligonucleotide.
16. A composition comprising the antisense compound of claim 2 and a pharmaceutically acceptable carrier or diluent.
17. The composition of claim 16 further comprising a colloidal dispersion system.
- 15 18. A method of inhibiting the expression of FXR in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 2 so that expression of FXR is inhibited.
19. A method of treating a human having a disease or condition associated with FXR comprising administering to said animal a
20 therapeutically or prophylactically effective amount of the antisense compound of claim 2 so that expression of FXR is inhibited.
20. The method of claim 19 wherein the disease or condition is diabetes.
21. The method of claim 19 wherein the disease or condition is an immunological disorder.

22. The method of claim 19 wherein the disease or condition is a cardiovascular disorder such as dyslipidemia and the symptoms thereof, atherosclerosis, low HDL, elevated LDL, hypercholesterolemia, gall stones, hypertriglyceridemia, and obesity.
- 5 23. The method of claim 19 wherein the disease or condition is a neurologic disorder.
24. The method of claim 19 wherein the disease or condition is ischemia/reperfusion injury.